The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials
Open accessAbstract
BACKGROUND: While long-acting injectable antipsychotics (LAIs) are hoped to reduce high relapse rates in schizophrenia, recent randomized controlled trials (RCTs) challenged the benefits of LAIs over oral antipsychotics (OAPs). METHODS: Systematic review/meta-analysis of RCTs that lasted ≥ 6 months comparing LAIs and OAPs. Primary outcome was study-defined relapse at the longest time point; secondary outcomes included relapse at 3, 6, 12, 18, and 24 months, all-cause discontinuation, discontinuation due to adverse events, drug inefficacy (ie, relapse + discontinuation due to inefficacy), hospitalization, and nonadherence. RESULTS: Across 21 RCTs (n = 5176), LAIs were similar to OAPs for relapse prevention at the longest time point (studies = 21, n = 4950, relative risk [RR] = 0.93, 95% confidence interval [CI]: 0.80-1.08, P = .35). The finding was confirmed restricting the analysis to outpatient studies lasting ≥ 1 year (studies = 12, RR = 0.93, 95% CI:0.71-1.07, P = .31). However, studies using first-generation antipsychotic (FGA)-LAIs (studies = 10, RR = 0.82, 95% CI:0.69-0.97, P = .02) and those published ≤ 1991 (consisting exclusively of all 8 fluphenazine-LAI studies; RR = 0.79, 95% CI: 0.65-0.96, P = 0.02) were superior to OAPs regarding the primary outcome. Pooled LAIs also did not separate from OAPs regarding any secondary outcomes. Again, studies using FGA-LAIs and those published ≤ 1991 were associated with LAI superiority over OAPs, eg, hospitalization and drug inefficacy. CONCLUSIONS: In RCTs, which are less representative of real-world patients than naturalistic studies, pooled LAIs did not reduce relapse compared with OAPs in schizophrenia patients. The exceptions were FGA-LAIs, mostly consisting of fluphenazine-LAI studies, which were all conducted through 1991. Because this finding is vulnerable to a cohort bias, studies comparing FGA-LAI vs second-generation antipsychotics-LAI and LAI vs OAP RCTs in real-world patients are needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics
Woods, S. W. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0607 · Cited by 2,050
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Self-citationDiscovering the Neural Basis of Human Social Anxiety: A Diagnostic and Therapeutic Imperative
Charney, D. S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.1 · Cited by 1,428
Robinson, D., Woerner, M. G., Alvir, J. M. J., Bilder, R., Goldman, R., Geisler, S., Koreen, A., Sheitman, B., Chakos, M., Mayerhoff, D., et al. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.3.241 · Cited by 1,327
Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G., & Davis, J. M. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60239-6 · Cited by 931 · cited 1×
“These included subgroups based on (1) medication group (FGA-LAI vs SGA-LAI), (2) publication year (older RCTs [published ≤1991] vs newer RCTs [published ≥2005]); there was a 14 year gap between the last study published in 1991 and the next study published in 2005, (3) treatment concealment (double-blind doubledummy vs…”
Self-citationTiihonen, J., Haukka, J., Taylor, M., Haddad, P. M., Patel, M. X., & Korhonen, P. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10081224 · Cited by 619
Lieberman, J. A., Perkins, D., Belger, A., Chakos, M., Jarskog, F., Boteva, K., & Gilmore, J. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01303-8 · Cited by 593
Leucht, S., Barnes, T. R. E., Kissling, W., Engel, R. R., Correll, C., & Kane, J. M. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.7.1209 · Cited by 517
Self-citationLeucht, S., Arbter, D., Engel, R. R., Kissling, W., & Davis, J. M. (2009) · Molecular Psychiatry · doi:10.1038/sj.mp.4002136 · Cited by 489
Leucht, C., Heres, S., Kane, J. M., Kissling, W., Davis, J. M., & Leucht, S. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2010.11.020 · Cited by 419
Self-citationAntipsychotic Medication Adherence: Is There a Difference Between Typical and Atypical Agents?
Dolder, C. R., Lacro, J. P., Dunn, L. B., & Jeste, D. V. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.1.103 · Cited by 386
Tiihonen, J., Walhbeck, K., Lönnqvist, J., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 385
Hogarty, G. E. (1979) · Archives of General Psychiatry · doi:10.1001/archpsyc.1979.01780120013001 · Cited by 365
Silvestri, S., Seeman, M. V., Negrete, J.-C., Houle, S., Shammi, C. M., Remington, G. J., Kapur, S., Zipursky, R. B., Wilson, A. A., Christensen, B. K., et al. (2000) · Psychopharmacology · doi:10.1007/s002130000532 · Cited by 311
van Haren, N. E. M., Hulshoff Pol, H. E., Schnack, H. G., Cahn, W., Mandl, R. C. W., Collins, D. L., Evans, A. C., & Kahn, R. S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301347 · Cited by 311
Samaha, A.-N., Seeman, P., Stewart, J., Rajabi, H., & Kapur, S. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5416-06.2007 · Cited by 262
Relationships Among Subjective and Objective Measures of Adherence to Oral Antipsychotic Medications
Velligan, D. I., Wang, M., Diamond, P., Glahn, D. C., Castillo, D., Bendle, S., Lam, Y. W. F., Ereshefsky, L., & Miller, A. L. (2007) · Psychiatric Services · doi:10.1176/appi.ps.58.9.1187 · Cited by 249
Long-Acting Risperidone and Oral Antipsychotics in Unstable Schizophrenia
Rosenheck, R. A., Krystal, J. H., Lew, R., Barnett, P. G., Fiore, L., Valley, D., Thwin, S. S., Vertrees, J. E., & Liang, M. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1005987 · Cited by 214
Kane, J. M., Detke, H. C., Naber, D., Sethuraman, G., Lin, D. Y., Bergstrom, R. F., & McDonnell, D. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2009.07081221 · Cited by 197
Self-citationFalloon, I., Watt, D. C., & Shepherd, M. (1978) · Psychological Medicine · doi:10.1017/s0033291700006632 · Cited by 196
Prevention of Relapse in Schizophrenia: An Evaluation of Fluphenazine Decanoate
Schooler, N. R. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780140018002 · Cited by 177
Rifkin, A. (1977) · Archives of General Psychiatry · doi:10.1001/archpsyc.1977.01770130045004 · Cited by 175
Kishimoto, T., Agarwal, V, Kishi, T., Leucht, S., Kane, J. M., & Correll, C. U. (2013) · Molecular Psychiatry · doi:10.1038/mp.2011.143 · Cited by 169
Self-citationClinical guideline recommendations for antipsychotic long-acting injections
Kane, J. M., & García-Ribera, C. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s63 · Cited by 150
Self-citationLess Is More: Antipsychotic Drug Effects Are Greater with Transient Rather Than Continuous Delivery
Samaha, A., Reckless, G. E., Seeman, P. M., Diwan, M., Nóbrega, J. N., & Kapur, S. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.01.010 · Cited by 121
Gäebel, W., Schreiner, A., Bergmans, P., de Arce, R., Rouillon, F., Cordes, J., Eriksson, L., & Smeraldi, E. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2010.111 · Cited by 119
Waddell, L., & Taylor, M. (2009) · The British Journal of Psychiatry · doi:10.1192/bjp.195.52.s43 · Cited by 118
Arango, C., Bombín, I., González-Salvador, T., García‐Cabeza, I., & Bobes, J. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.07.006 · Cited by 96
Grimaldi‐Bensouda, L., Rouillon, F., Astruc, B., Rossignol, M., Bénichou, J., Falissard, B., Limosin, F., Beaufils, B., Vaïva, G., Verdoux, H., et al. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.10.022 · Cited by 91
Bai, Y. M., Chen, T. T., Chen, J. Y., Wu, W.-H., Hung, C. H., & Lin, W. K. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0808 · Cited by 91
Keks, N. A., Ingham, M., Khan, A., & Karcher, K. (2007) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.105.017020 · Cited by 85
Controlled Trial of Depot Fluphenazine in Out-patient Schizophrenics
Crawford, R. S., & Forrest, A. D. (1974) · The British Journal of Psychiatry · doi:10.1192/bjp.124.4.385 · Cited by 73
Remington, G. J., Seeman, P. M., Feingold, A., Mann, S. W., Shammi, C., & Kapur, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05866yel · Cited by 69
Prevention of Recidivism of Schizophrenics Treated with Fluphenazine Enanthate
del Giudice, J., Clark, W. G., & Gocka, E. F. (1975) · Psychosomatics · doi:10.1016/s0033-3182(75)71232-x · Cited by 60
Prevention of Relapse in Schizophrenia
Geddes, J. R. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201033460112 · Cited by 58
Ascher‐Svanum, H., Peng, X., Faries, D., Conley, R. R., & Schuh, K. J. (2011) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s16061 · Cited by 55
Correll, C. U., Kishimoto, T., & Kane, J. M. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.2/ccorrell · Cited by 54
Self-citationLong-Acting Injectable Risperidone
Ehret, M. J., & Fuller, M. A. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e085 · Cited by 49
Lambert, T. J. R., Olivares, J. M., Peuskens, J., DeSouza, C., Kozma, C. M., Otten, P., Crivera, C., Jacobs, A., Macfadden, W., Mao, L., et al. (2011) · Annals of General Psychiatry · doi:10.1186/1744-859x-10-10 · Cited by 45
Macfadden, W., Yw, M., Haskins, J. T., Bossie, C. A., & Alphs, L. D. (2010) · PubMed · Cited by 42
Barnes, T. R. E., Milavić, G., Curson, D. A., & Platt, S. D. (1983) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/bf00583530 · Cited by 38
Glick, I. D., & Marder, S. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0515 · Cited by 28
The place of observational studies in assessing the effectiveness of depot antipsychotics
Haddad, P. M., Tiihonen, J., Haukka, J. K., Taylor, M., Patel, M. X., & Korhonen, P. (2011) · Schizophrenia Research · doi:10.1016/j.schres.2011.05.022 · Cited by 22
Schooler, N. R. (2012) · Schizophrenia Research · doi:10.1016/s0920-9964(12)70019-1 · Cited by 10
Research works printed but not linked: 10
- 2009, The British Journal of Psychiatry, 52, S63
- 2009, The British Journal of Psychiatry, 52, S43
- 2010, Psychiatry, 7, 23
- 1989, PHARMACEUT J, 243, 431
- 1996, CHIN J NERV MENTAL DIS, 22, 9
- DEL GIUDICE, 1975, Psychosomatics, 16, 32, 10.1176/appi.psy.16.1.32 · doi:10.1176/appi.psy.16.1.32
- Peng, 2011, 3, 9
- 2009, JPN J CLIN PSYCHOPHARMACOL, 12, 1199
- 1991, RINSHO HYOKA CLINICAL EVALUATION, 19, 15
- 2008, The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP), 11, 158
Cited by
Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017
Hiemke, C., Bergemann, N., Clement, H., Conca, A., Deckert, J., Domschke, K., Eckermann, G., Egberts, K., Gerlach, M., Greiner, C., et al. (2018) · Pharmacopsychiatry · doi:10.1055/s-0043-116492 · Cited by 1,446
Kahn, R. S., Sommer, I. E., Murray, R. M., Meyer-Lindenberg, A., Weinberger, D. R., Cannon, T. D., O'Donovan, M., Correll, C. U., Kane, J. M., van Os, J., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.67 · Cited by 1,124
Self-citationTiihonen, J., Mittendorfer-Rutz, E., Majak, M., Mehtälä, J., Hoti, F., Jedenius, E., Enkusson, D., Leval, A., Sermon, J., Tanskanen, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1322 · Cited by 670
Improving outcomes of first‐episode psychosis: an overview
Fusar‐Poli, P., McGorry, P. D., & Kane, J. M. (2017) · World Psychiatry · doi:10.1002/wps.20446 · Cited by 575
Self-citationSchizophrenia: overview and treatment options.
(2014) · PubMed Central · Cited by 533
Metadata
- Authors
- Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J. M., & Correll, C. U.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-17
- Volume
- 40
- Issue
- 1
- Pages
- 192-213
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- OpenAlex
- W2143285031
- Cited by
- 395
- References
- 48
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.